Having trouble accessing articles? Reset your cache.

Arena falls on lorcaserin briefing documents

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) fell $2.72 (40%) to $4.13 on Tuesday after FDA questioned the efficacy and safety of lorcaserin in briefing documents posted ahead of Thursday's Metabolic and Endocrine

Read the full 304 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE